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Dimerization of the Sodium/Iodide Symporter
Rebecca J. Thompson,1,2 Alice Fletcher,1,2 Katie Brookes,1,2 Hannah Nieto,1,2 Mohammed M. Alshahrani,1,2
Jonathan W. Mueller,1,2 Nicholas H.F. Fine,1,2 David J. Hodson,1,2 Kristien Boelaert,1,2
Martin L. Read,1,2 Vicki E. Smith,1,2,* and Christopher J. McCabe,1,2,*
Background: The ability of thyroid follicular epithelial cells to accumulate iodide via the sodium/iodide symporter
(NIS) is exploited to successfully treat most thyroid cancers, although a subset of patients lose functional NIS activity
and becomeunresponsive to radioiodide therapy,with poor clinical outcome.Our knowledgeofNIS regulation remains
limited, however. While numerous membrane proteins are functionally regulated via dimerization, there is little
definitive evidenceofNISdimerization, andwhether thismight impactupon radioiodideuptakeand treatment success is
entirely unknown. We hypothesized that NIS dimerizes and that dimerization is a prerequisite for iodide uptake.
Methods:Coimmunoprecipitation, proximity ligation, and Fo¨rster resonance energy transfer (FRET) assays were used
to assess NIS:NIS interaction. To identify residues involved in dimerization, a homology model of NIS structure was
built based on the crystal structure of the dimeric bacterial protein vSGLT.
Results: Abundant cellular NIS dimerization was confirmed in vitro via three discrete methodologies. FRET and
proximity ligation assays demonstrated that while NIS can exist as a dimer at the plasma membrane (PM), it is also
apparent in other cellular compartments. Homology modeling revealed one key potential site of dimeric interaction,
with six residues<3A˚ apart. In particular,NIS residuesY242,T243, andQ471were identifiedas critical to dimerization.
Individual mutation of residues Y242 and T243 rendered NIS nonfunctional, while abrogation of Q471 did not impact
radioiodide uptake. FRET data show that the putative dimerization interface can tolerate the loss of one, but not two, of
these three clustered residues.
Conclusions:We show for the first time that NIS dimerizes in vitro, and we identify the key residues via which this
happens. We hypothesize that dimerization of NIS is critical to its trafficking to the PM and may therefore represent a
new mechanism that would need to be considered in overcoming therapeutic failure in patients with thyroid cancer.
Keywords: NIS, radioiodide uptake, dimerization, thyroid
Introduction
At least a quarter of patients with differentiated thyroidcancer (DTC) do not concentrate radioiodide (131I) suffi-
ciently for effective ablation therapy (1,2), which remains a
particular problem in metastatic disease. There are essentially
two groups of thyroid cancer patients: those who respond to
radioiodide treatment and therefore have an excellent prognosis,
and those who do not respond and for whom outcome is dire (3).
Troublingly, DTC is now the most rapidly increasing cancer in
the United Kingdom and the United States, with*300,000 new
cases reported worldwide per year. More than 40,000 people
will die from thyroid cancer this year (4).
Mechanisms that influence treatment success in those
thyroid cancers that are radioiodide resistant have been de-
scribed in numerous investigations. While clinical progress is
being made (5–8), the underlying causes of treatment failure
are still not fully understood and the pathogenic processes
associated with radioiodine resistance in individual patients
or lesions need to be delineated.
Radioiodide uptake is mediated via the sodium/iodide
symporter (NIS). Decreased levels of NIS expression and/or
diminished targeting of NIS to the plasma membrane (PM) of
thyroid cancer cells represent the principal mechanisms of
radioiodide-refractory disease (9–11). Numerous studies
have addressed the common pathways of NIS regulation
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in vitro and in vivo (12–17). Other studies have investigated
the key transcriptional and epigenetic alterations that silence
thyroid-specific genes such as NIS (15,18–21). To actively
transport iodide for thyroid hormone biosynthesis and
radioiodide treatment, NIS must be present in the basolateral
PM of thyroid follicular cells. However, relatively little is
known about the mechanisms that govern the trafficking of
NIS or its intrinsic preference as a monomeric or multimeric
protein.
Multiple membrane proteins are functionally regulated via
dimerization (22–27), and circumstantial evidence has pre-
viously suggested that NIS may dimerize. For example, using
freeze-fracture electron microscopy, intramembrane parti-
cles in NIS-expressing oocytes were deemed to be too large
to be monomers (28).
The most detailed appraisal of the potential for NIS to di-
merize was carried out by Huc-Brandt et al. (29). Electro-
phoresis patterns of NIS were suggestive of dimerization, and
size exclusion chromatography and light scattering analyses
also supported the notion that NIS may dimerize in vitro (29).
In fact, the majority of NIS species had molecular weights
corresponding to those of putative dimers and higher multi-
mers, suggesting that NIS exists mainly in multimeric form
(29). However, to what extent dimerization of NIS influences
function and how this might impact upon radioiodide uptake in
patients with thyroid cancer remain unclear.
We hypothesized that NIS dimerizes and that dimerization
is critical to NIS function. We challenged the putative di-
merization of NIS through three separate technologies and
modeled potential sites of NIS:NIS interaction. Our data
show that NIS does indeed dimerize and that abrogation of
key dimeric residues renders NIS unable to transport iodide,
findings that now warrant investigation in patients with DTC.
Materials and Methods
Cell lines
The SW1736 human anaplastic thyroid carcinoma cell line
was kindly supplied by Dr. Rebecca Schweppe (University of
Colorado) and maintained in RPMI 1640 medium (Thermo
Fisher Scientific, Waltham, MA). The HeLa human cervical
carcinoma cell line was acquired from European Collection of
Authenticated Cell Cultures (ECACC, Porton Down, United
Kingdom) and maintained in high-glucose Dulbecco’s modi-
fied Eagle’s medium (Sigma, St. Louis, MO). Both were
supplemented with 10% fetal bovine serum (Thermo Fisher
Scientific), penicillin (105 U/L), and streptomycin (100mg/L).
Plasmids, transfection, and mutagenesis
The full-length human NIS cDNA was cloned in the
pcDNA3.1+ vector with a C-terminal MYC (NIS-MYC) or
HA (NIS-HA) tag (30). NIS-MYC and NIS-HA were both
required for the coimmunoprecipitation (co-IP) and prox-
imity ligation assays (PLAs), which necessitated two distinct
tags. For use in the Fo¨rster resonance energy transfer (FRET)
experiments, NIS cDNA was inserted into the HindIII and
BamHI restriction sites of the cerulean-N1 and citrine-N1
vectors (gifts from Michael Davidson & Dave Piston ob-
tained from Addgene, Watertown, MA) to create NIS con-
structs conjugated at the C-terminus to a cerulean or citrine
fluorophore, respectively.
Transfections were performed with TransIT-LT1 re-
agent (Geneflow, Lichfield, United Kingdom) following the
manufacturer’s protocol at a 3:1 reagent to DNA ratio and
experiments performed after 48 hours. Specific mutations
were made as indicated using the QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent Technologies, Santa
Clara, CA).
Immunofluorescence staining and PLA
Immunofluorescence staining was conducted as described
previously (30). Primary antibodies used were mouse mono-
clonal anti-MYC-Tag 9B11 (1:750; Cell Signaling Tech-
nology, Danvers, MA), rabbit monoclonal anti-HA Y-11
(1:100; Santa Cruz, Dallas, TX), mouse monoclonal anti-HA
16B12 (1:100; BioLegend, San Diego, CA), rabbit mono-
clonal anti-Na+/K+/ATPase (Alexa Fluor 488), EP1845Y
(1:50; Abcam, Cambridge, United Kingdom), and rabbit
monoclonal anti-Na+/K+/ATPase EP1845Y (1:250; Abcam).
A Zeiss LSM 510 confocal microscope with · 40 objective
was used to perform confocal microscopy (Carl Zeiss AG,
Oberkochen, Germany). Epifluorescent microscopy was
performed using · 40 objective on a Leica DM6000 fluores-
cent microscope (Leica Microsystems, Wetzlar, Germany).
The Duolink In Situ Fluorescence Protocol with Detection
Reagents Red Kit (Sigma) was used as per the manufacturer’s
instructions. Cells were transfected for 48 hours before fix-
ation, permeabilization, and addition of anti-MYC and anti-
HA antibodies.
Western blotting
Cells were harvested in RIPA (50mM Tris-HCl, pH 7.4,
150mM NaCl, 1% vol/vol Igepal CA-630, 6mM sodium
deoxycholate, 1mM EDTA) with a protease inhibitor cock-
tail (Sigma). Western blotting was performed as described
previously (31). Proteins (20lg) were separated by SDS-
PAGE (sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis) using 12% acrylamide gels. Primary antibodies
used were rabbit polyclonal anti-NIS (1:1000; Proteintech,
Rosemont, IL), mouse monoclonal anti-MYC-Tag 9B11
(1:1000; Cell Signaling Technology), rabbit monoclonal
anti-HA Y-11 (1:1000; Santa Cruz), and mouse monoclonal
b-actin AC-15 (1:10,000; Sigma).
Radioiodide uptake assays
Cells were seeded into 24-well plates and transfected as
above. Radioiodide uptake assays were performed 48 hours
after transfection as described previously (32). Briefly, 1lM
NaI and 0.05 lCi 125I were added directly to the cell medium.
After incubation at 37C for 1 hour, medium was removed
and cells were washed rapidly with Hanks’ balanced salt
solution. Cells were lysed in 2% SDS, and the radioactivity of
the lysate was counted for one minute in a gamma counter.
Results are given as picomoles of I- per microgram of pro-
tein. To demonstrate specific uptake, the NIS inhibitor so-
dium perchlorate was used at 100lM to pretreat control wells
for 1 hour before the addition of radioiodide.
Homology modeling of NIS dimerization
The 3D structure of the NIS sequence was generated in
Phyre2, based on two protein templates: the two dimeric
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vSGLT structures [PDB ID: 2XQ2 (33) and 3DH4 (34)] were
used with 100% confidence of sequence homology between
NIS and template sequence. Using these templates, 74% NIS
residues were modeled at >90% confidence, with 95 residues
modeled ab initio. Subsequent alignment of this NIS struc-
ture with the crystal structure of vSGLT [PBD ID: 2XQ2
(33)] in YASARA revealed a homology model, with a root-
mean-square deviation (RMSD) of atomic positions of
1.178A˚, indicating a relatively small distance between the
backbone atoms of the two aligned protein structures. To
improve the homology model of NIS dimerization, the re-
gions of NIS sequence that could not be aligned onto the
vSGLT crystal structure needed to be identified and removed.
To achieve this, six different topology predictions were
performed on the NIS primary sequence to identify which
regions of NIS are likely to form transmembrane domains
(TMDs), as TMDs are well structured and therefore more
accurate to model. To improve homology between the two
proteins, the large intracellular C-terminal tail of NIS (from
S556 onward) was removed. To further improve homology,
the large extracellular domain between TMDs 12 and 13
(from T472 to Y524) was also removed from the NIS se-
quence. The 3D structure of this modified NIS sequence,
generated as above, gave a more refined homology model of
NIS structure, with 93% residues modeled at >90% confi-
dence and just 33 residues modeled ab initio, and an RMSD
of 0.993A˚.
Fo¨rster resonance energy transfer
Cells were seeded in eight-well chambered cover glass
(Lab-Tek Nunc; Thermo Fisher Scientific) and cotransfected
with NIS variants conjugated to either cerulean or citrine.
FRET imaging was performed 48 hours post-transfection
using Crest X-Light spinning disk head coupled to a Nikon
Ti-E automated base and 60· /1.40 NA objective. Confocal
microscopy was performed and three concurrent versions of
each image were captured: total cerulean image (cerulean
excitation/cerulean emission [CFP/CFP]), total citrine image
(citrine excitation/citrine emission [YFP/YFP]), and FRET
image (cerulean excitation/citrine emission [CFP/YFP]).
Excitation was delivered at k = 430–450 nm for cerulean and
at k = 500–520 nm for citrine using a Lumencor Spectra X
Light Engine, and emitted signals detected at k = 460–500 nm
for cerulean and at k = 535–565 nm for citrine using a Pho-
tometrics Evolve Delta 512 EMCCD.
Data analysis was performed using MetaMorph Version
7.8.13.0 software (Molecular Devices, Wokingham, United
Kingdom). Background subtraction was performed on im-
ages before further analysis. Controls were carried out to
determine YFP and CFP cross talk into the FRET image.
Cells expressing citrine alone were imaged as above. A re-
gion of interest (ROI) was drawn around each cell and the
ratio of the average gray level of the ROI in the FRET image
to that in the YFP image was calculated as per Equation (a)
below to determine YFP cross talk. To determine CFP cross
talk, cells expressing cerulean alone were imaged as above
and the ratio of the average gray level of the ROI in the FRET
image to that in the CFP image was calculated as per Equa-
tion (b). (a) YFP cross talk = FRET imageO YFP image; (b)
CFP cross talk = FRET imageO CFP image. Once the extent
of YFP and CFP cross talk into the FRET image was estab-
lished, Equation (c) below was then used to correct for YFP
and CFP cross talk in cells expressing both fluorophores. (c)
Corrected FRET = FRET image - (YFP image ·YFP cross
talk) - (CFP image ·CFP cross talk).
Statistical analyses
Data were analyzed using one-way ANOVA with Dun-
nett’s multiple comparison test to compare with wild type
(WT), or Tukey’s multiple comparison test to compare all
means. If data were nonparametric, Kruskal–Wallis multiple
comparison test was used instead. Two-way ANOVA with
Sidak’s multiple comparison test was also used. Significance
was taken as p < 0.05.
Results
co-IP of dimeric NIS in vitro
We used three separate strategies to evaluate the potential
NIS:NIS interaction, (i) co-IP assays, (ii) PLAs, and (iii)
FRET assays, and utilized both a thyroid (SW1736) and
nonthyroid (HeLa) cell line. First, we tagged NIS with either
an HA or an MYC tag on the N- or C-terminus. Initial ex-
periments showed that C-terminal tagging was generally
preferable to N-terminal tagging in terms of protein detection,
normal subcellular localization, and impact upon radioiodide
uptake (data not shown). NIS tagged C-terminally with HA or
MYC was functional in SW1736 and HeLa cells (Fig. 1A),
and yielded canonical unglycosylated (*60 kDa) and gly-
cosylated (*75 to *90 kDa) monomeric forms under re-
ducing conditions of Western blotting (Supplementary
Fig. S1).
We then progressed to co-IP assays in SW1736 and HeLa
cells. When we pulled back with an anti-MYC antibody and
immunoblotted using an anti-HA antibody, we observed a
band of between 135 and 180 kDa in lanes with NIS-MYC
and NIS-HA coexpression, but not in control lanes (Fig. 1B-
i). A band of a similar size was often observed in the lysate of
cells transfected with either NIS-MYC or NIS-HA through
Western blotting and is therefore likely to demonstrate the
presence of NIS-MYC:NIS-MYC and NIS-HA:NIS-HA
homodimers (Supplementary Fig. 2).
Reciprocal co-IPs, where we immunoprecipitated with
anti-HA antibody and probed using anti-MYC antibody, re-
vealed consistent findings with dimeric bands of *135 to
180 kDa in lanes with NIS-MYC and NIS-HA coexpression,
but not in control lanes (Fig. 1B-ii). Thus, forward and re-
verse co-IP assays in two cell lines reveal the apparent in-
teraction between NIS-MYC and NIS-HA heterodimers.
PLA determination of the subcellular sites
of NIS dimerization
Next, we challenged our findings through PLAs, which
detect subcellular proximity between proteins if they are
separated by fewer than 40 nm (35,36). Using anti-MYC and
anti-HA antibodies in SW1736 and HeLa cells transfected
with both NIS-MYC and NIS-HA, red spots of specific
NIS:NIS interaction were apparent, whereas no binding was
detected in cells transfected with NIS-MYC or NIS-HA alone
(Fig. 1C). Confocal microscopy revealed the subcellular lo-
calization of NIS-HA:NIS-MYC interaction to be predomi-
nantly cytoplasmic, with some clear PM binding.
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To address PM localization more specifically, we per-
formed PLAs and then carried out confocal immunofluores-
cent microscopy in the same fixed cells (Fig. 1D). Staining
for the sodium/potassium adenosine triphosphatase (Na+/K+-
ATPase), a solute pump that regulates intracellular sodium
and potassium at the PM and hence is critical to NIS function,
revealed discrete areas of colocalization at the PM, where the
Na+/K+-ATPase is predominantly active. However, coloca-
lization between the dimeric NIS (NIS-MYC:NIS-HA) and
Na+/K+-ATPase was also apparent in intracellular compart-
ments, suggesting that NIS does not exist as a dimer exclu-
sively at the PM.
Quantification of NIS dimerization via FRET
Having shown through co-IP assays and PLAs that we
could detect the specific binding of HA-tagged and MYC-
tagged NIS in vitro, we next carried out FRET assays as a
final confirmatory method of detecting NIS dimerization.
Furthermore, through using confocal microscopy to detect
the transfer of fluorescent light energy between bound pro-
teins that are within 10 nm of each other, FRET assays would
facilitate the quantification of NIS dimerization. We made
constructs conjugating the fluorophore citrine (Cit) or ceru-
lean (Cer) to the C- and N-termini of NIS and assessed NIS
functionality. Only C-terminally tagged NIS elicited signifi-
cant radioiodide uptake (Fig. 2A) and yielded the fully pro-
cessed NIS protein (Supplementary Fig. S3).
After correcting for cross talk between the citrine and ceru-
lean fluorophores, which was calculated as 23.1% and 43.7%,
respectively (see the Materials and Methods section), coex-
pression of the NIS-fluorophore constructs (NIS-Cer +NIS-Cit)
resulted in a significant increase in corrected FRET signal (ar-
bitrary units) compared with negative control cells (CerCit)
expressing both the free fluorophores (SW1736: 430.62– 32.74
[NIS-CerCit] vs. -882.00– 88.16 [CerCit], p< 0.001; HeLa:
357.60– 33.50 [NIS-CerCit] vs. -380.54– 134.00 [CerCit],
p< 0.01; Fig. 2B). Thus, fluorophoreswere only able to undergo
FRET when they were conjugated to NIS, signifying that the
twoNISmonomerswere in close enoughproximity to dimerize.
Two positive control systems for FRET confirmed specific
detection of binding (Supplementary Fig. S4). FRETdata hence
confirmed our co-IP and PLA findings of NIS dimerization.
To elucidate the subcellular location of NIS dimerization,
FRET analysis was performed on linear sections across
SW1736 and HeLa cells cotransfected with NIS-cerulean and
NIS-citrine and plotted against distance along the line. Al-
though there were clear regions of intense apparent dimer-
ization at the PM (Fig. 2C; arrowed in top panel), on average
the FRET signal appeared to be distributed fairly evenly
across the width of N= 20 cells assessed. FRET data were
therefore consistent with PLA findings in that NIS dimer-
ization occurs both in the cytosol and at the PM.
Predicting the key amino acid residues
for NIS dimerization
As co-IP, PLA, and FRET data had all supported the notion
that NIS does in fact dimerize, we set about trying to identify
the specific regions or motifs of NIS responsible for interac-
tion. While not empirically investigated previously, a leucine
zipper motif is apparent in TMD 6 of NIS (37) and a putative
glycine zipper motif (GZM) in TMD 12. However, while ab-
rogation of each domain resulted in a decreased ability to
uptake radioiodide in both SW1736 and HeLa cells, PLA and
FRET demonstrated that leucine and glycine zipper mutants
retained the ability to dimerize (Supplementary Fig. S5).
To therefore identify de novo residues involved in dimer-
ization, a homology model of NIS structure based on the
crystal structure of the bacterial protein vSGLT was built
using the modeling platform Phyre2 (see the Materials and
Methods section for details). The crystal structure of the
solute transporter vSGLT (34) has been used previously to
model monomeric NIS (38). As the crystal structure of
vSGLT is dimeric, we then threaded NIS residues on to this to
create a 3Dmodel of dimerized NIS. Our modeling identified
eight residues predicted to be fewer than 0.3 nm from the
opposing monomer (D237, Y242, T243, F244, Q471, A525,
K554, R555; Fig. 3A). Interestingly, these amino acids were
not directly proximal to residues previously shown to be
critical to iodide or sodium transport (Fig. 3B, C). This
therefore hints that dimerization of NIS is not required as a
structural prerequisite for iodide uptake.
The functional consequences of abrogating putative
residues implicated in dimerization
Based on the modeling of Figure 3, we considered the
region containing D237, Y242, T243, F244, Q471, and A525
to be a ‘‘hot-spot’’ of potential dimerization, and to identify
whether these residues might be involved in dimerization, we
made the following point mutations: D237A, Y242A,
T243A, Q471A, and A525F. With the exception of Q471A,
which had a similar banding pattern to WT, the proportion of
FIG. 1. (A) Cells were transfected with empty pcDNA3.1+ vector (VO) or differentially tagged NIS variants and
radioiodide uptake assays performed. Significant radioiodide uptake compared with VO was observed with both MYC- and
HA-tagged NIS variants. Pretreatment with sodium perchlorate (NaClO4) to inhibit NIS (gray bars) demonstrates NIS-
specific iodide uptake in black bars. Bars show mean radioiodide uptake in pmol 125I/lg protein –SEM. (B) Representative
co-IP assays demonstrating direct interaction between NIS-MYC and NIS-HA in SW1736 and HeLa cells. Cells were
transfected with VO (lane 1), VO+NIS-MYC (lane 2), VO+NIS-HA (lane 3), or NIS-MYC+NIS-HA (lanes 4 and 5) and
lysed. Co-IP was performed on all lysates (except no antibody control, lane 4) with mouse anti-MYC (i) or rabbit anti-HA
(ii). Western blot using antibody to the other tag detected the presence of the other NIS variant, demonstrating a direct
interaction between the two NIS variants (co-IP blots, top panel). (C) PLAs with and without DAPI staining for nuclei
(blue) demonstrating close proximity (<40 nm) between NIS-MYC and NIS-HA throughout the cell, including the PM. (D)
PLAs with Na+K+ATPase immunofluorescent staining. Areas of colocalization (yellow; white arrowheads) between PLA
signal generated by close proximity of NIS-MYC and NIS-HA (in red) and the PM marker Na+K+ATPase (in green) in
representative SW1736 (left) and HeLa (right) cells were apparent. *p< 0.05. co-IP, coimmunoprecipitation; NIS, sodium/
iodide symporter; PLAs, proximity ligation assays; PM, plasma membrane; SEM, standard error of the mean.
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glycosylated versus nonglycosylated NIS was visibly lower
for all mutants compared with WT, suggesting that mutating
the majority of the putative dimerization interface residues
impairs NIS protein maturation (Fig. 4A and Supplementary
Fig. S6), although expression and glycosylation patterns were
variable between the two cell lines under our standard re-
ducing Western blotting conditions.
Immunofluorescence microscopy using anti-Na+/K+/AT-
Pase as a PM marker revealed that while WT and Q471
showed PM localization, no membrane localization was ob-
served for the mutants D237A or A525F (Fig. 4B and Sup-
plementary Fig. S7). Similarly, the vast majority of Y242A
and T243A NIS protein was intracellularly retained. Col-
lectively these data imply that mutations in the putative di-
merization interface usually impair the maturation of NIS and
its trafficking to the PM, with the exception of Q471A.
Functionally, the radioiodide uptake of mutant Q471Awas
similar to or greater than WT in both cell lines (Fig. 4C),
whereas uptake of the remaining mutants was significantly
lower than WT. This appears to reflect the expression of the
fully glycosylated, mature form of NIS (Fig. 4A and Sup-
plementary Fig. S6). Finally, NIS dimerization was assessed
via PLA and FRET in SW1736 and HeLa cells. All mutants
retained the ability to homodimerize (Fig. 4D), although
Q471A showed a marginal decrease in whole-cell FRET
signal in SW1736s (Fig. 4E). Thus, mutation of individual
residues, which lie within this putative region, does not im-
pede the ability of NIS monomers to homodimerize but may
impair NIS maturation and, consequently, function.
The putative dimerization interface can tolerate the
loss of one, but not two, of the three clustered residues
‘‘Stick’’ modeling of amino acid residues revealed that the
putative dimerization interface comprises residues on two
separate extracellular loops: the third (D237, Y242, and
T243) and the sixth (Q471 and A525) loops. Residues on the
third extracellular loop on one monomer (in magenta) are in
closest proximity to those of the sixth extracellular loop on
the opposite monomer (in cyan; Fig. 5A). Of these residues,
Q471 (red), Y242 (yellow), and T243 (orange) seem to
cluster together ([1]; circled in brown; Fig. 5A), while A525
(green) and D237 (blue) appear to form a separate cluster
([2]; circled in gray).
Acting upon this apparent proximity, FRET was carried out
on combinations of residues that formed the most proximal
pairings. A statistically significant reduction in corrected
FRET compared with WT was observed for two of the com-
binations in both cell lines: Q471A+Y242A (SW1736:mean-
241.68, range -997.58 to 411.97, p< 0.05; HeLa: mean-
82.14, range -516.51 to 354.33, p< 0.05) and Q471A+T242A
(SW1736: mean- 349.69, range -986.66 to 168.42, p< 0.001;
HeLa: mean- 104.45, range -424.75 to 158.84, p< 0.01;
Fig. 5B). However, there was no significant change in cor-
rected FRET compared with WT for the remaining two
combinations of A525F+D237A or A525F+Y242A in either
cell line. Representative FRET images are given in Figure 5B.
While not quantified empirically, PLA demonstrated
similarly reduced red spots of dimerization for the combi-
nations of Q471A+Y242A and Q471A+T242A compared
with WT (Fig. 5C). Collectively, these observations suggest
that the interactions between residues Q471A, Y242A, and
T243A within the primary putative dimerization interface are
critical for NIS dimerization, and mutation of the most
proximal residues of extracellular loops 3 and 6 significantly
impairs dimerization.
NIS function in response to disrupted dimerization
Finally, we assessed the functional impact of altering the
ability of NIS to dimerize, although these experiments are
complicated by the fact that up to five different NIS species
theoretically exist in each individual combination treatment
(one homodimer of each NIS mutant; one heterodimer; and
one monomer of each mutant). We first examined each in-
dividual mutation (Q471A, Y242A, T243A, and A525F) in
combination with WT. Our data of Figure 4D show that
Q471A retains radioiodide uptake, while Y242A, T243A,
and A525F all show significantly impaired function. When
combined with WT NIS, Q471A gave radioiodide uptake
values indistinguishable fromWT in SW1736 cells (Fig. 5D),
whereas Y242A, T243A, and A525F showed nonsignifi-
cantly reduced uptake. Consistent data were apparent in
HeLa cells (Supplementary Fig. S8).
When we appraised the functional consequence of NIS
mutants that FRET had revealed to show significantly re-
duced heterodimerization, we discovered that there was no
significant impact on radioiodide uptake (Fig. 5D) unless two
nonfunctional mutants were combined (A525F+Y242A),
where iodide uptake was markedly lost (Fig. 5D).
We thus propose the following potential rules: (i) NIS
dimerization is relatively ‘‘strong’’ and needs at least two
matching and opposing mutations to disrupt it. (ii) While NIS
does not need to be fully processed or glycosylated to di-
merize, this is the predominant dimeric form under WT
conditions, based on co-IP data; (iii) For appreciable 125I
FIG. 2. (A) SW1736 (left) and HeLa (right) cells were transfected with VO or one differentially tagged NIS variant and
radioiodide uptake assays were performed. Pretreatment with sodium perchlorate (w. NaClO4) was used to specifically
inhibit NIS activity (gray bars). (B) Representative images from FRET analysis of SW1736 cells transfected with ceru-
lean+citrine (Cer+Cit, negative control) and NIS-cerulean+NIS-citrine (NIS-Cer+NIS-Cit; left). Right—coexpression of
both NIS-fluorophore constructs gave significantly greater corrected FRET signals than the negative control, demonstrating
a close proximity between the two fluorophores that is indicative of dimerization. Bars show mean corrected FRET signal in
arbitrary units and error bars show SEM. One-way ANOVA with Tukey’s multiple comparison statistical tests was
performed: **p < 0.01, ****p< 0.001 (n = 5 with 10 individual cells in each n). (C) SW1736 (left) and HeLa (right) cells
were transfected with NIS-cerulean+NIS-citrine and FRET analysis was performed on linear sections across the cell
(image). Arrowheads indicate examples of prominent regions of NIS dimerization at the PM. Graphs depict the corrected
FRET signal across the lines, suggesting that NIS dimerization occurs throughout the cell (n= 5 cells measured per
experiment). *p < 0.05. FRET, Fo¨rster resonance energy transfer.
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FIG. 3. (A) Eight novel residues were identified as potentially involved in NIS dimerization using the refined NIS
homology model, appearing to form two distinct putative dimerization interfaces, a larger (‘‘primary’’) region circled in red
and smaller (‘‘secondary’’) region in blue. Side-chains of residues found to be <3A˚ from the opposing monomer are shown
in ‘‘Stick’’ form, and monomers are colored cyan or magenta. Structures are viewed in the membrane plane oriented so the
extracellular milieu is above the structure. Amino and carboxy termini are labeled (N and C, respectively). Inset—magnified
regions of closest interaction. (B) Residues known to be involved in sodium or iodide binding and are shown in ‘‘Stick’’
form and colored in magenta and cyan, respectively, while remaining residues are colored in gray. Structures are viewed in
the membrane plane oriented so the extracellular milieu is above the dimer. (C) The putative dimeric structure viewed from
the extracellular side.
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uptake, at least one NIS monomer must be fully processed/
glycosylated (e.g., Q471A+Y242A); if neither are fully pro-
cessed, then no radioiodide uptake is possible, despite the
fact that the monomers can dimerize (e.g., A525F+Y242A).
(iv) Dimerization may potentially occur before processing/
glycosylation. Subsequently, if at least one of the monomeric
NIS molecules is processed/glycosylated, the dimer can then
be trafficked to the PM where radioiodide uptake can occur.
Discussion
The factors regulating the function of NIS are of direct
clinical importance due to its central role in radioiodide
treatment; patients with radioiodide-refractory (RAIR) thyr-
oid cancer, particularly those with metastatic disease, have a
life expectancy of 3–5 years and represent a group for whom
there remains a clear unmet medical need (1,2). TSH (thy-
rotropin) induces iodide uptake through upregulation of NIS
expression and the modulation of its subcellular localization
(39–41). Many thyroid cancers demonstrate reduced NIS
activity through diminished PM retention (42–44). BRAF-
mutant tumors (60–70% of thyroid cancers) are more likely
to be resistant to radioiodide, partly due to decreased NIS
expression (13,45), but also due to impaired PM targeting
(11,14) through mechanisms that remain ill-defined. Indeed,
PTTG1 Binding Factor (PBF;PTTG1IP) is the only protein
currently known to bind to NIS and modulate its subcellular
localization (30).
Numerous PM proteins have been reported to dimerize and
for this to be integral to their trafficking and/or PM function
(22–27,29). However, although several previous studies have
directly or indirectly addressed the putative dimerization of
NIS, the evidence to date remains circumstantial, particularly
as they have relied on the use of extracted proteins and cannot
exclude the possibility of nonspecific protein aggregation.
We therefore sought to determine whether NIS does in fact
dimerize, what structure it forms, and what its impact might
be on its canonical function.
For the first time, we show via three discrete methodolo-
gies that NIS does in fact dimerize in vitro. Co-IP, PLA, and
FRET data all consistently revealed abundant and detectable
cellular dimerization of NIS. This was not confined to par-
ticular cellular compartments, but appeared to occur gener-
ally within the cytoplasm, as well as at the PM. It is not clear
from these studies whether NIS dimerizes early in its traf-
ficking to the PM, or whether it internalizes from the PM as a
dimer.
Indeed, when we used FRET to quantify the intensity of
dimerized NIS in cross sections of cells, no clear patterns
emerged in keeping with PLA data. In our experience, NIS
does not appear uniformly at the PM, but rather in discrete
regions of higher intensity (30,32). Rapid spiking of peaks and
troughs in the FRET signal may reflect vesicles of NIS being
trafficked through the cell, possibly suggesting that NIS may
be trafficking as a dimer. Therefore, our hypothesis is that NIS
dimerizes in the endoplasmic reticulum (ER), progresses to the
Golgi where various posttranslational modifications occur, and
then is preferentially trafficked as a dimer to the PM.
Another member of the SLC5A protein family, the high-
affinity choline transporter (CHT1), has been demonstrated
to dimerize. The authors proposed that this dimerization may
be mediated by a GZMwithin TMD 12 as this motif is highly
conserved in members of the SLC5A family (46), including
NIS where the putative GZM comprised glycine residues at
positions 444 and 448. However, our data reveal that mu-
tating the putative leucine and GZMs did not alter NIS di-
merization and our homology model of NIS dimerization
revealed that they were not in close proximity to our proposed
sites of monomer:monomer binding. As these dimerization
motifs are known to be important for helical packing (47),
and as our mutants of these motifs resulted in proteins that
could no longer be processed and trafficked to the PM, it is
possible that these motifs are instead crucial for the proper
folding of the TMDs of the NIS monomer.
In assessing the function of NIS mutants that cannot di-
merize, radioiodide uptake findings are hampered by the
obvious difficultly in discerning the individual physiological
effects of monomeric and dimeric NIS. In combining mutants
of the dimerization interface (e.g., Q471A+T243A, which
gave the lowest FRET signal), individual mutants are still
able to homodimerize (i.e., Q471A:Q471A; T243A:T243A)
and will also exist as monomers (Q471A, T243A). Further-
more, it is difficult to know whether a nonfunctional mutant
(e.g., A525F), which does not reach the PM, loses function
because of a lack of dimerization or else nonspecifically due
to altered cellular processing (such as ER-associated degra-
dation, nonsense-mediated decay, and protein instability).
Thus, experiments designed to determine whether the
significantly impaired dimerization of these two mutants
specifically alters iodide transport are encumbered by mul-
tiple other protein events occurring simultaneously in the
cell. Until we can specifically define the effect of NIS di-
merization on its function, its importance remains to be fully
determined.
FIG. 4. (A) Mutating residues within the putative dimerization interface alter NIS glycosylation. Western blots were
performed on SW1736 and HeLa cell lysates with HA-tagged WT and mutant NIS expression using the mouse anti-NIS
antibody. A band at 75–100 kDa represents the fully glycosylated mature form of NIS, while a band at*60 kDa represents
the nonglycosylated immature form of NIS. (B) NIS localization of HA-tagged NIS mutation of individual residues of the
putative dimerization interface. Immunofluorescence analysis was performed using the mouse anti-HA primary antibody to
visualize NIS (green), while the rabbit anti-Na+/K+/ATPase primary antibody was used as a PM marker (red). Nuclei are
visualized in blue using Hoechst stain, 40·magnification. (C) Radioiodide uptake is abolished when residues within the
putative dimerization interface are mutated, with the exception of Q471A, in SW1736 and HeLa cells. Bars represent mean
relative radioiodide uptake relative to WT – SEM. *p< 0.005, **p < 0.0005, and ***p < 0.0001 compared with WT (n= 3
with 4 replicates in each n). (D) PLA signal is still observed in HeLa cells when single residues in the putative dimerization
interface are mutated, 40·magnification. (E) Corrected FRET values when residues of the putative dimerization interface
were mutated. Data presented as box and whisker plots, with the center line indicating the mean corrected FRET value (in
arbitrary units), the box representing the 25th and 75th percentiles, and the whiskers denoting the minimum and maximum
values. *p < 0.05. n = 2, with a minimum of 20 cells analyzed in each n. WT, wild type.
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However, what our data do show is that NIS dimerization is
contingent upon three key residues: Y242 and T243 of one
monomer, and Q471 of the other. A single mutation of one of
these residues is insufficient to prevent interaction, but a
combined mutation of Y242+Q471 or T243+Q471 results in
significantly impaired interaction. Q471A retained iodide up-
take activity and was correctly targeted to the PM, suggesting
that individual mutations within the putative dimerization in-
terface do not necessarily preclude PM targeting. Indeed, while
the Y242A and T243A mutants were largely intracellularly
10 THOMPSON ET AL.
FIG. 5. (A) Detailed examination of the primary putative dimerization interface. Two distinct clusters of residues are
particularly close and are shown in different planes of view. Cluster 1 (circled in brown) comprises Q471 (red) of the cyan
monomer and Y242 (yellow) and T243 (orange) of the opposite magenta monomer. Cluster 2 (circled in gray) comprises
A525 (green) of the cyan monomer and D237 (blue) and potentially Y242 of the opposite magenta monomer. (B) FRET
analysis of combined putative dimerization interface mutants in SW1736 and HeLa cells cotransfected with differentially
tagged (either cerulean or citrine) variants of WT NIS or a combination of two NIS mutants (n = 2, with a minimum of 20
cells analyzed in each n). Representative images captured during FRET analysis are shown. Three concurrent versions of
each image were taken: total cerulean (CFP) image (cerulean excitation/cerulean emission [CFP/CFP]), total citrine (YFP)
image (YFP excitation/YFP emission [YFP/YFP]), and the FRET image (cerulean excitation/citrine emission [CFP/YFP]).
(C) Reduced PLA signal was observed with combinations of mutations within the NIS putative dimerization interface in
HeLa cells, 40 ·magnification. (D) Radioiodine uptake in SW1736 cells in response to various combinations of co-
transfected WT and mutant NIS. As indicated, each bar represents the possibility of multiple simultaneous monomeric and
dimeric NIS species. **p < 0.01, compared with WT:WT. N = 3 experiments. *p < 0.05, **p< 0.01, ***p < 0.001.
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retained, a small proportion of both mutants were still apparent
via immunofluorescence microscopy at the PM.
In summary, we show that NIS can exist as a monomeric
and dimeric protein in vitro, substantiating earlier circum-
stantial evidence (28,29,42,48,49). We propose that residues
on the third extracellular loop of one NIS monomer are in
closest proximity to those of the sixth extracellular loop on the
opposite monomer and that this is where binding occurs. The
role of dimerization remains unclear, but in keeping with other
PM proteins (22–27), we hypothesize that dimerization aids
trafficking to the PM. Whether patients with RAIR thyroid
cancer show impaired dimerization of NIS and whether this
contributes to the frequently observed reduction in NIS lo-
calization to the PM in DTC now need to be determined.
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